Bavarian Nordic A/S (BAVA.CO)
- Previous Close
155.90 - Open
153.25 - Bid 154.50 x --
- Ask 154.70 x --
- Day's Range
150.85 - 157.35 - 52 Week Range
123.30 - 300.00 - Volume
191,332 - Avg. Volume
276,802 - Market Cap (intraday)
12.022B - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
12.26 - EPS (TTM)
12.60 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
265.67
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
www.bavarian-nordic.comRecent News: BAVA.CO
View MorePerformance Overview: BAVA.CO
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAVA.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAVA.CO
View MoreValuation Measures
Market Cap
12.13B
Enterprise Value
10.08B
Trailing P/E
12.37
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.13
Price/Book (mrq)
1.06
Enterprise Value/Revenue
1.76
Enterprise Value/EBITDA
6.02
Financial Highlights
Profitability and Income Statement
Profit Margin
17.28%
Return on Assets (ttm)
4.60%
Return on Equity (ttm)
9.09%
Revenue (ttm)
5.72B
Net Income Avi to Common (ttm)
987.98M
Diluted EPS (ttm)
12.60
Balance Sheet and Cash Flow
Total Cash (mrq)
2.18B
Total Debt/Equity (mrq)
1.39%
Levered Free Cash Flow (ttm)
-421M